NASDAQ:ATHXAthersys Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.37 -0.22 (-8.49 %) (As of 08/11/2020 12:45 PM ET) Add Compare Share Today's Range$2.31Now: $2.37▼$2.4950-Day Range$1.97MA: $2.72▼$3.0852-Week Range$1.13Now: $2.37▼$4.38Volume52,766 shsAverage Volume2.74 million shsMarket Capitalization$465.66 millionP/E RatioN/ADividend YieldN/ABeta-1.7 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases. It also has license and collaboration agreements with RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAthersys has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Athersys has a potential upside of 279.7% from its current price of $2.37.Amount of Analyst CoverageAthersys has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAthersys has received 356 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAthersys has received 310 “underperform” votes. (Add your “underperform” vote.)Community SentimentAthersys has received 53.45% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote “Outperform” if you believe ATHX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAthersys does not currently pay a dividend.Dividend GrowthAthersys does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Athersys insiders have bought 630.77% more of their company's stock than they have sold. Specifically, they have bought $418,000.00 in company stock and sold $57,200.00 in company stock.Percentage Held by InsidersOnly 12.60% of the stock of Athersys is held by insiders.Percentage Held by InstitutionsOnly 17.19% of the stock of Athersys is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Athersys are expected to grow in the coming year, from ($0.32) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Athersys is -7.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athersys is -7.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAthersys has a P/B Ratio of 15.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.97 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATHX Previous Symbol CUSIPN/A CIK1368148 Webwww.athersys.com Phone216-431-9900Debt Debt-to-Equity RatioN/A Current Ratio2.36 Quick Ratio2.36Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.63 million Price / Sales82.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book15.80Profitability EPS (Most Recent Fiscal Year)($0.29) Net Income$-44,580,000.00 Net MarginsN/A Return on Equity-184.41% Return on Assets-104.23%Miscellaneous Employees75 Outstanding Shares196,480,000Market Cap$465.66 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $2.37 -0.22 (-8.49 %) (As of 08/11/2020 12:45 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ATHX News and Ratings via Email Sign-up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter. Athersys (NASDAQ:ATHX) Frequently Asked Questions How has Athersys' stock been impacted by Coronavirus? Athersys' stock was trading at $1.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATHX stock has increased by 93.8% and is now trading at $2.48. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Athersys? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Athersys. When is Athersys' next earnings date? Athersys is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Athersys. How were Athersys' earnings last quarter? Athersys, Inc. (NASDAQ:ATHX) posted its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.02. View Athersys' earnings history. What price target have analysts set for ATHX? 4 analysts have issued 12 month target prices for Athersys' stock. Their forecasts range from $5.00 to $14.00. On average, they expect Athersys' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 262.9% from the stock's current price. View analysts' price targets for Athersys. Has Athersys been receiving favorable news coverage? News stories about ATHX stock have trended neutral on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Athersys earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Athersys. Who are some of Athersys' key competitors? Some companies that are related to Athersys include Xencor (XNCR), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Intercept Pharmaceuticals (ICPT), Seres Therapeutics (MCRB), I-Mab (IMAB), Revance Therapeutics (RVNC), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Myovant Sciences (MYOV), IGM Biosciences (IGMS), Y-mAbs Therapeutics (YMAB), Ironwood Pharmaceuticals (IRWD) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of Athersys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Novavax (NVAX), Vaxart (VXRT), Opko Health (OPK), Rigel Pharmaceuticals (RIGL), SLS International (SLS) and AEterna Zentaris (AEZS). Who are Athersys' key executives? Athersys' management team includes the following people: Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 58)Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA, Pres, COO & Sec. (Age 53)Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 52)Ms. Laura K. Campbell, Sr. VP of Fin. (Age 55)Karen Hunady, Director of Corp. Communications & Investor Relations What is Athersys' stock symbol? Athersys trades on the NASDAQ under the ticker symbol "ATHX." Who are Athersys' major shareholders? Athersys' stock is owned by a variety of retail and institutional investors. Top institutional investors include Coastal Investment Advisors Inc. (0.44%), GW&K Investment Management LLC (0.29%), Swiss National Bank (0.21%), M&G Investment Management Ltd. (0.11%), Cedar Brook Financial Partners LLC (0.10%) and NEXT Financial Group Inc (0.09%). Company insiders that own Athersys stock include John J Harrington, Kenneth H Traub, Laura K Campbell and William Lehmann Jr. View institutional ownership trends for Athersys. Which major investors are selling Athersys stock? ATHX stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Russell Investments Group Ltd., and MAI Capital Management. Company insiders that have sold Athersys company stock in the last year include John J Harrington, Laura K Campbell, and William Lehmann Jr. View insider buying and selling activity for Athersys. Which major investors are buying Athersys stock? ATHX stock was purchased by a variety of institutional investors in the last quarter, including Swiss National Bank, Rafferty Asset Management LLC, Coastal Investment Advisors Inc., New York State Common Retirement Fund, State Board of Administration of Florida Retirement System, Nisa Investment Advisors LLC, GW&K Investment Management LLC, and Arizona State Retirement System. View insider buying and selling activity for Athersys. How do I buy shares of Athersys? Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Athersys' stock price today? One share of ATHX stock can currently be purchased for approximately $2.48. How big of a company is Athersys? Athersys has a market capitalization of $487.27 million and generates $5.63 million in revenue each year. The biopharmaceutical company earns $-44,580,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Athersys employs 75 workers across the globe. What is Athersys' official website? The official website for Athersys is www.athersys.com. How can I contact Athersys? Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
